CORALVILLE, Iowa, Sept. 19, 2016 /PRNewswire/ -- Immortagen, Inc. announced today that it has successfully completed its Series A financing. Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine. These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment. Immortagen’s product pipeline fills a key gap as more and more patient tumors are sequenced, and genetic analysis of the data is required. Founded by a team of leading physician-researchers and complemented with proven management, Immortagen believes it will fill a key gap in the global oncology market.
Related Files
ImmortaPressFinl for Series A 8-1-16-1-2.docx
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immortagen-inc-completes-series-a-financing-for-personalized-medicine-300330524.html
SOURCE Immortagen, Inc.
